Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
8.88M | 9.83M | 8.81M | 10.30M | 5.44M | 8.37M | Gross Profit |
6.41M | 6.79M | 4.90M | 6.31M | 3.62M | 5.72M | EBIT |
-6.69M | -7.11M | -8.83M | -7.38M | -7.45M | -4.00M | EBITDA |
-6.59M | -6.96M | -8.68M | -7.30M | -7.36M | -3.90M | Net Income Common Stockholders |
-4.62M | -6.93M | -8.71M | -7.12M | -7.49M | -7.66M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
743.43K | 5.95M | 8.72M | 14.76M | 14.22M | 1.52M | Total Assets |
6.40M | 11.37M | 13.70M | 19.81M | 19.57M | 6.56M | Total Debt |
0.00 | 395.98K | 497.04K | 586.59K | 942.60K | 15.98K | Net Debt |
-743.43K | -2.58M | -8.22M | -14.18M | -13.28M | -1.50M | Total Liabilities |
4.87M | 3.36M | 3.70M | 3.59M | 3.46M | 4.93M | Stockholders Equity |
1.54M | 8.01M | 10.23M | 16.37M | 16.20M | 1.70M |
Cash Flow | Free Cash Flow | ||||
-2.66M | -5.33M | -6.04M | -4.03M | -7.01M | -1.79M | Operating Cash Flow |
-2.65M | -5.33M | -6.03M | -4.02M | -6.98M | -1.78M | Investing Cash Flow |
2.46M | -2.97M | -8.53K | -15.19K | -21.44K | -9.92K | Financing Cash Flow |
2.80M | 2.56M | -8.54K | 4.57M | 19.71M | 2.56M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $21.75B | 46.95 | 9.61% | 1.01% | -0.17% | -17.34% | |
73 Outperform | $177.21B | 70.41 | 15.62% | ― | 17.24% | 27.76% | |
59 Neutral | $143.59M | ― | -144.19% | ― | 0.55% | -8.47% | |
55 Neutral | $71.66M | ― | -63.82% | ― | -9.49% | 39.20% | |
49 Neutral | $15.95M | ― | -153.37% | ― | -6.17% | 8.27% | |
48 Neutral | $6.86B | 1.11 | -50.22% | 2.47% | 16.71% | 1.53% | |
36 Underperform | $240.21K | ― | ― | -32.57% | -15.03% |
Mr. Giandomenico Trombetta, a director at Milestone Scientific Inc., has resigned from the board effective immediately due to personal reasons and other pressing matters. His departure is not due to any disagreements with the company’s operations, finances, policies, or practices, suggesting a stable operational outlook despite the leadership change.
Milestone Scientific Inc. announced the retirement of CEO Arjan Haverhals, effective December 31, 2024, as he seeks to spend more time with his family and pursue personal interests. Neal Goldman, Chairman of the Board, will serve as Interim CEO while an independent search firm identifies a permanent successor. Haverhals will remain a director and consultant, ensuring a smooth leadership transition. The company aims to accelerate the commercialization of its CompuFlo® Epidural System, building on the solid foundation established under Haverhals’ leadership.